CONMED (CNMD) 10-Q 26 Apr 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 24, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	CONMED CORPORATION
Entity Central Index Key	0000816956
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		28,231,270

Consolidated Condensed Statemen

Consolidated Condensed Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net sales	$ 218,378	$ 202,064
Cost of sales	96,940	92,507
Gross profit	121,438	109,557
Selling and administrative expense	99,226	84,568
Research and development expense	10,575	7,711
Operating expenses	109,801	92,279
Income from operations	11,637	17,278
Other expense	4,225	0
Interest expense	9,369	4,818
Income (loss) before income taxes	(1,957)	12,460
Provision (benefit) for income taxes	(2,978)	1,803
Net income	1,021	10,657
Comprehensive income	$ 1,096	$ 13,402
Per share data:
Basic (in dollars per share)	$ 0.04	$ 0.38
Diluted (in dollars per share)	$ 0.04	$ 0.37
Weighted average common shares:
Basic (shares)	28,173	28,008
Diluted (shares)	29,034	28,573

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 23,407	$ 17,511
Accounts receivable, net	172,195	181,550
Inventories	171,087	154,599
Prepaid expenses and other current assets	24,020	20,691
Total current assets	390,709	374,351
Property, plant and equipment, net	116,976	113,245
Goodwill	615,152	400,440
Other intangible assets, net	547,025	413,193
Other assets	90,975	67,909
Total assets	1,760,837	1,369,138
Current liabilities:
Current portion of long-term debt	14,385	18,336
Accounts payable	54,491	53,498
Accrued compensation and benefits	29,998	42,924
Other current liabilities	52,397	46,186
Total current liabilities	151,271	160,944
Long-term debt	803,555	438,564
Deferred income taxes	76,604	81,061
Other long-term liabilities	36,350	26,299
Total liabilities	1,067,780	706,868
Commitments and contingencies
Shareholders' equity:
Preferred stock, par value $.01 per share; authorized 500,000 shares; none outstanding	0	0
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2019 and 2018, respectively	313	313
Paid-in capital	374,555	341,738
Retained earnings	460,229	464,851
Accumulated other comprehensive loss	(55,662)	(55,737)
Less: 3,077,735 and 3,167,422 shares of common stock in treasury, at cost in 2019 and 2018, respectively	(86,378)	(88,895)
Total shareholders’ equity	693,057	662,270
Total liabilities and shareholders’ equity	$ 1,760,837	$ 1,369,138

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	31,299,194	31,299,194
Treasury stock, shares (in shares)	3,077,735	3,167,422

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Balance at period start (shares) at Dec. 31, 2017			31,299
Balance at period start at Dec. 31, 2017		$ 631,432	$ 313	$ 333,795	$ 440,085	$ (49,078)	$ (93,683)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans		657		(1,344)			2,001
Stock-based compensation		2,303		2,303
Dividends on common stock ($0.20 per share)		(5,606)			(5,606)
Comprehensive income (loss):
Foreign currency translation adjustments		649				649
Pension liability, net of income tax		510				510
Cash flow hedging gain (loss), net of income tax		1,586				1,586
Net income		10,657			10,657
Total comprehensive income		13,402
Balance at period end (shares) at Mar. 31, 2018			31,299
Balance at period end at Mar. 31, 2018		642,628	$ 313	334,754	445,576	(46,333)	(91,682)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of change in accounting principle | Accounting Standards Update 2014-09	[1]	440			440
Balance at period start (shares) at Dec. 31, 2018			31,299
Balance at period start at Dec. 31, 2018		662,270	$ 313	341,738	464,851	(55,737)	(88,895)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans		1,748		(769)			2,517
Stock-based compensation		2,703		2,703
Dividends on common stock ($0.20 per share)		(5,643)			(5,643)
Convertible note discount (net of income tax expense)		39,145		39,145
Convertible note hedge, (net of income tax benefit)		(38,829)		(38,829)
Issuance of warrants		30,567		30,567
Comprehensive income (loss):
Foreign currency translation adjustments		(578)				(578)
Pension liability, net of income tax		547				547
Cash flow hedging gain (loss), net of income tax		106				106
Net income		1,021			1,021
Total comprehensive income		1,096
Balance at period end (shares) at Mar. 31, 2019			31,299
Balance at period end at Mar. 31, 2019		$ 693,057	$ 313	$ 374,555	$ 460,229	$ (55,662)	$ (86,378)
[1]	We recorded the cumulative impact of adopting ASU 2014-09, Revenue from Contracts with Customers, in 2018. See Note 16 for further discussion regarding the adoption of these accounting standards.

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Dividends per share of common stock (in dollars per share)	$ 0.20	$ 0.20
Pension liability, tax	$ 173	$ 162
Cash flow hedging gain (loss), tax	34	505
Paid-in Capital
Convertible Note Discount Income Tax Expense (Benefit)	12,470	0
Convertible Note Hedge Income Tax Expense (Benefit)	$ (12,369)	$ 0

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income	$ 1,021	$ 10,657
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	4,442	4,502
Amortization of debt discount	1,510	0
Amortization	12,905	10,749
Stock-based compensation	2,703	2,303
Deferred income taxes	(4,699)	(736)
Loss on early extinguishment of debt	300	0
Increase (decrease) in cash flows from changes in assets and liabilities:
Accounts receivable	13,733	10,145
Inventories	(11,971)	(4,615)
Accounts payable	(1,776)	8,006
Accrued compensation and benefits	(13,695)	(7,052)
Other assets	(10,047)	(9,758)
Other liabilities	1,654	821
Total operating	(4,941)	14,365
Net cash provided by (used in) operating activities	(3,920)	25,022
Cash flows from investing activities:
Purchases of property, plant and equipment	(4,022)	(3,783)
Payments related to business acquisition, net of cash acquired	(364,928)	0
Net cash used in investing activities	(368,950)	(3,783)
Cash flows from financing activities:
Payments on term loan	(144,375)	(3,281)
Proceeds from term loan	265,000	0
Payments on revolving line of credit	(342,000)	(49,000)
Proceeds from revolving line of credit	299,000	24,000
Proceeds from convertible notes	345,000	0
Payments related to contingent consideration	(2,859)	0
Payments related to debt issuance costs	(16,210)	0
Dividends paid on common stock	(5,626)	(5,592)
Purchases of convertible hedges	(51,198)	0
Proceeds from issuance of warrants	30,567	0
Other, net	1,655	577
Net cash provided by (used in) financing activities	378,954	(33,296)
Effect of exchange rate changes on cash and cash equivalents	(188)	566
Net increase (decrease) in cash and cash equivalents	5,896	(11,491)
Cash and cash equivalents at beginning of period	17,511	32,622
Cash and cash equivalents at end of period	23,407	21,131
Non-cash investing and financing activities:
Contractual obligations from asset acquisition	5,500	10,000
Dividends payable	$ 5,643	$ 5,606

Operations

Operations	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operations	Operations

Interim Financial Information

Interim Financial Information	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim financial information	Interim Financial Information The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion of management, necessary for the fair statements of the results for the periods presented. The consolidated condensed financial statements herein consist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results for the period ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 . The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2018 included in our Annual Report on Form 10-K.

Business Acquisition

Business Acquisition	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Business Acquisition	Business Acquisition On February 11, 2019 we acquired Buffalo Filter, LLC and all of the issued and outstanding common stock of Palmerton Holdings, Inc. from Filtration Group FGC LLC (the "Buffalo Filter Acquisition") for approximately $365 million in cash. Buffalo Filter develops, manufactures and markets smoke evacuation technologies that are complementary to our general surgery offering. The acquisition was funded through a combination of cash on hand and long-term borrowings as further described below. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the Buffalo Filter Acquisition. The assessment of fair value is based on preliminary valuations and estimates that were available to management at the time the consolidated condensed financial statements were prepared. Accordingly, the allocation of purchase price is preliminary and therefore subject to adjustment during the measurement adjustment period. Cash $ 119 Other current assets 9,315 Current assets 9,434 Property, plant & equipment 4,036 Deferred income taxes 80 Goodwill 214,793 Customer relationships 125,000 Developed technology 9,000 Trademarks & tradenames 7,000 Other non-current assets 166 Total assets acquired $ 369,509 Current liabilities assumed 4,462 Total liabilities assumed 4,462 Net assets acquired $ 365,047 The goodwill recorded as part of the acquisition primarily represents revenue synergies, as well as operating efficiencies and cost savings. Goodwill deductible for tax purposes is $214.8 million . The weighted amortization period for intangibles acquired is 16 years. Customer relationships, developed technology and trademarks and tradenames are being amortized over a weighted average life of 16 , 10 and 20 years , respectively. The unaudited pro forma information for the quarters ended March 31, 2019 and 2018 , assuming Buffalo Filter Acquisition occurred as of January 1, 2018 are presented below. This information has been prepared for comparative purposes only and does not purport to be indicative of the results of operations which actually would have resulted had the Buffalo Filter acquisition occurred on the dates indicated, or which may result in the future. Three Months Ended March 31, 2019 2018 Net sales $ 223,397 $ 211,273 Net income (loss) 8,745 (3,210 ) These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, and acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services as well as integration costs such as severance and retention. Acquisition related costs included in the determination of pro forma net income for the three months ended March 31, 2018 included $0.7 million in cost of goods sold and $7.2 million included in selling and administrative expenses on the consolidated condensed statement of comprehensive income. Such amounts are excluded from the determination of pro forma net income for the three months ended March 31, 2019 . Net sales associated with Buffalo Filter of $6.1 million have been recorded in the consolidated condensed statement of comprehensive income for the three months ended March 31, 2019 . It is impracticable to determine the earnings recorded in the consolidated condensed statement of comprehensive income for the three months ended March 31, 2019

Revenues

Revenues	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended March 31, 2019 March 31, 2018 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 45,256 $ 71,770 $ 117,026 $ 43,152 $ 63,099 $ 106,251 Americas (excluding the United States) 15,042 7,462 22,504 16,771 7,679 24,450 Europe, Middle East & Africa 30,402 15,930 46,332 28,302 12,984 41,286 Asia Pacific 22,737 9,779 32,516 20,637 9,440 30,077 Total sales from contracts with customers $ 113,437 $ 104,941 $ 218,378 $ 108,862 $ 93,202 $ 202,064 Timing of Revenue Recognition Goods transferred at a point in time $ 104,739 $ 104,425 $ 209,164 $ 100,791 $ 92,881 $ 193,672 Services transferred over time 8,698 516 9,214 8,071 321 8,392 Total sales from contracts with customers $ 113,437 $ 104,941 $ 218,378 $ 108,862 $ 93,202 $ 202,064 Contract liability balances related to the sale of extended warranties to customers are as follows: March 31, 2019 December 31, 2018 Contract liability $ 12,027 $ 11,043 Revenue recognized during the three months ended March 31, 2019 and March 31, 2018 from amounts included in contract liabilities at the beginning of the period were $2.3 million and $1.8 million , respectively. There were no material contract assets as of March 31, 2019 and December 31, 2018

Comprehensive Income

Comprehensive Income	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Comprehensive Income	Comprehensive Income Comprehensive income consists of the following: Three Months Ended March 31, 2019 2018 Net income $ 1,021 $ 10,657 Other comprehensive income (loss): Pension liability, net of income tax (income tax expense of $173 and $162 for the three months ended March 31, 2019 and 2018, respectively) 547 510 Cash flow hedging gain, net of income tax (income tax expense of $34 and $505 for the three months ended March 31, 2019 and 2018, respectively) 106 1,586 Foreign currency translation adjustment (578 ) 649 Comprehensive income $ 1,096 $ 13,402 Accumulated other comprehensive loss consists of the following: Cash Flow Hedging Gain (Loss) Pension Liability Cumulative Translation Adjustments Accumulated Other Comprehensive Income (Loss) Balance, December 31, 2018 $ 4,085 $ (31,718 ) $ (28,104 ) $ (55,737 ) Other comprehensive income (loss) before reclassifications, net of tax 1,318 (578 ) 740 Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,598 ) 720 — (878 ) Income tax 386 (173 ) — 213 Net current-period other comprehensive income (loss) 106 547 (578 ) 75 Balance, March 31, 2019 $ 4,191 $ (31,171 ) $ (28,682 ) $ (55,662 ) Cash Flow Hedging Gain (Loss) Pension Liability Cumulative Translation Adjustments Accumulated Other Comprehensive Income (Loss) Balance, December 31, 2017 $ (3,530 ) $ (25,813 ) $ (19,735 ) $ (49,078 ) Other comprehensive income (loss) before reclassifications, net of tax 629 — 649 1,278 Amounts reclassified from accumulated other comprehensive income (loss) before tax a 1,262 672 — 1,934 Income tax (305 ) (162 ) — (467 ) Net current-period other comprehensive income (loss) 1,586 510 649 2,745 Balance, March 31, 2018 $ (1,944 ) $ (25,303 ) $ (19,086 ) $ (46,333 ) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 6 and Note 12

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments We enter into derivative instruments for risk management purposes only. We operate internationally and in the normal course of business are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures. By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties. Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs. We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them. The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation March 31, 2019 December 31, 2018 Forward exchange contracts Cash flow hedge $ 155,730 $ 155,313 Forward exchange contracts Non-designated 42,977 39,631 The remaining time to maturity as of March 31, 2019 is within two years for designated foreign exchange contracts and approximately one month for non-designated forward exchange contracts. Statement of comprehensive income presentation Derivatives designated as cash flow hedges Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) and net earnings on our consolidated condensed statement of comprehensive income and our consolidated condensed balance sheet: Amount of Gain (Loss) Recognized in AOCI Statement of Consolidated Condensed of Comprehensive Income Amount of Gain (Loss) Reclassified from AOCI Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, Total Amount of Line Item Presented Derivative Instrument 2019 2018 Location of amount reclassified 2019 2018 2019 2018 Foreign exchange contracts $ 1,738 $ 829 Net Sales $ 218,378 $ 202,064 $ 1,497 $ (1,413 ) Cost of Sales 96,940 92,507 101 151 Pre-tax gain (loss) $ 1,738 $ 829 $ 1,598 $ (1,262 ) Tax expense (benefit) 420 200 386 (305 ) Net gain (loss) $ 1,318 $ 629 $ 1,212 $ (957 ) At March 31, 2019 , $4.0 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months. Derivatives not designated as cash flow hedges Net gains and losses from derivative instruments not accounted for as hedges offset by gains and losses on our intercompany receivables on our condensed consolidated statements of earnings were: Three Months Ended March 31, Derivative Instrument Location on Consolidated Condensed Statement of Comprehensive Income 2019 2018 Net gain (loss) on currency hedge contracts Selling and administrative expense $ (181 ) $ (69 ) Net gain (loss) on currency transaction exposures Selling and administrative expense $ (229 ) $ (127 ) Balance sheet presentation We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at March 31, 2019 and December 31, 2018 : March 31, 2019 Location on Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Fair Value Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 5,291 $ (65 ) $ 5,226 Foreign exchange contracts Other long-term assets 428 (128 ) 300 $ 5,719 $ (193 ) $ 5,526 Derivatives not designated as hedging instruments: Foreign exchange contracts Prepaids and other current assets 14 (102 ) (88 ) Total derivatives $ 5,733 $ (295 ) $ 5,438 December 31, 2018 Location on Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Fair Value Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 5,817 $ (431 ) $ 5,386 Derivatives not designated as hedging instruments: Foreign exchange contracts Prepaids and other current assets 19 (217 ) (198 ) Total derivatives $ 5,836 $ (648 ) $ 5,188 Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated condensed balance sheets. Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model. Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets in markets that are not active; inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions. Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2019 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: March 31, December 31, Raw materials $ 49,366 $ 45,898 Work-in-process 18,476 15,000 Finished goods 103,245 93,701 Total $ 171,087 $ 154,599

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights ("SARs") during the period. The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2019 and 2018 : Three Months Ended March 31, 2019 2018 Net income $ 1,021 $ 10,657 Basic – weighted average shares outstanding 28,173 28,008 Effect of dilutive potential securities 861 565 Diluted – weighted average shares outstanding 29,034 28,573 Net income (per share) Basic $ 0.04 $ 0.38 Diluted 0.04 0.37 The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 0.3 million and 0.4 million for the three months ended March 31, 2019 and 2018 . As more fully described in Note 17 , our 2.625% convertible notes due in 2024 (the “Notes”) are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. As a result of convertible note hedge transactions, potential dilution upon conversion of the Notes occurs when the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price of the convertible note hedge transactions ( $114.92 ). As of March 31, 2019

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Leases The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and applied the modified retrospective approach to adoption whereby the standard is applied only to the current period. The Company leases various manufacturing facilities, office facilities and equipment under operating and finance leases. We determine if an arrangement is a lease at inception. Right-of-use ("ROU") assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Certain of our leases include variable lease payments, mainly when a lease is tied to an index rate. These variable lease payments are recorded as expense in the period incurred and are not material. The Company has lease agreements with lease and non-lease components, which we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The related short-term lease expense is not material. Our leases have remaining lease terms of one year to twelve years , some of which include options to extend the leases for up to five years , and some of which include options to terminate the leases within one year. We only account for such extensions or early terminations when it is reasonably certain we will exercise such options. Lease costs consists of the following: Three Months Ended, March 31, 2019 Operating lease cost $ 1,996 Finance lease cost: Depreciation 53 Interest on lease liabilities 7 Total finance lease cost 60 Total lease cost $ 2,056 Supplemental balance sheet information related to leases is as follows: March 31, 2019 Operating leases Other assets (net of lease impairment of $1,325) $ 16,277 Other current liabilities $ 6,810 Other long-term liabilities 11,133 Total operating lease liabilities $ 17,943 Finance leases Property, plant and equipment, gross $ 1,131 Accumulated depreciation (302 ) Property, plant and equipment, net $ 829 Current portion of long-term debt $ 299 Long-term debt 244 Total finance lease liabilities $ 543 Weighted average remaining lease term (in years) Operating leases 3.80 years Finance leases 3.83 years Weighted average discount rate Operating leases 4.41 % Finance leases 4.90 % Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,123 Financing cash flows from finance leases 93 Right-of-use assets obtained in exchange for lease obligations: Operating leases 444 Finance leases — Maturities of lease liabilities as of March 31, 2019 are as follows: Finance Lease Operating Lease Remaining, 2019 $ 260 $ 6,026 2020 219 4,921 2021 21 3,063 2022 76 2,419 2023 — 1,549 2024 — 718 Thereafter — 770 Total lease payments 576 19,466 Less imputed interest (33 ) (1,523 ) Total lease liabilities $ 543 $ 17,943 As of March 31, 2019, we have no additional operating or finance leases that have not yet commenced. Maturities of lease liabilities under ASC 840 are consistent with the above disclosure.
Leases	Leases The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and applied the modified retrospective approach to adoption whereby the standard is applied only to the current period. The Company leases various manufacturing facilities, office facilities and equipment under operating and finance leases. We determine if an arrangement is a lease at inception. Right-of-use ("ROU") assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Certain of our leases include variable lease payments, mainly when a lease is tied to an index rate. These variable lease payments are recorded as expense in the period incurred and are not material. The Company has lease agreements with lease and non-lease components, which we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The related short-term lease expense is not material. Our leases have remaining lease terms of one year to twelve years , some of which include options to extend the leases for up to five years , and some of which include options to terminate the leases within one year. We only account for such extensions or early terminations when it is reasonably certain we will exercise such options. Lease costs consists of the following: Three Months Ended, March 31, 2019 Operating lease cost $ 1,996 Finance lease cost: Depreciation 53 Interest on lease liabilities 7 Total finance lease cost 60 Total lease cost $ 2,056 Supplemental balance sheet information related to leases is as follows: March 31, 2019 Operating leases Other assets (net of lease impairment of $1,325) $ 16,277 Other current liabilities $ 6,810 Other long-term liabilities 11,133 Total operating lease liabilities $ 17,943 Finance leases Property, plant and equipment, gross $ 1,131 Accumulated depreciation (302 ) Property, plant and equipment, net $ 829 Current portion of long-term debt $ 299 Long-term debt 244 Total finance lease liabilities $ 543 Weighted average remaining lease term (in years) Operating leases 3.80 years Finance leases 3.83 years Weighted average discount rate Operating leases 4.41 % Finance leases 4.90 % Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,123 Financing cash flows from finance leases 93 Right-of-use assets obtained in exchange for lease obligations: Operating leases 444 Finance leases — Maturities of lease liabilities as of March 31, 2019 are as follows: Finance Lease Operating Lease Remaining, 2019 $ 260 $ 6,026 2020 219 4,921 2021 21 3,063 2022 76 2,419 2023 — 1,549 2024 — 718 Thereafter — 770 Total lease payments 576 19,466 Less imputed interest (33 ) (1,523 ) Total lease liabilities $ 543 $ 17,943 As of March 31, 2019, we have no additional operating or finance leases that have not yet commenced. Maturities of lease liabilities under ASC 840 are consistent with the above disclosure.
Leases	Leases The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and applied the modified retrospective approach to adoption whereby the standard is applied only to the current period. The Company leases various manufacturing facilities, office facilities and equipment under operating and finance leases. We determine if an arrangement is a lease at inception. Right-of-use ("ROU") assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Certain of our leases include variable lease payments, mainly when a lease is tied to an index rate. These variable lease payments are recorded as expense in the period incurred and are not material. The Company has lease agreements with lease and non-lease components, which we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The related short-term lease expense is not material. Our leases have remaining lease terms of one year to twelve years , some of which include options to extend the leases for up to five years , and some of which include options to terminate the leases within one year. We only account for such extensions or early terminations when it is reasonably certain we will exercise such options. Lease costs consists of the following: Three Months Ended, March 31, 2019 Operating lease cost $ 1,996 Finance lease cost: Depreciation 53 Interest on lease liabilities 7 Total finance lease cost 60 Total lease cost $ 2,056 Supplemental balance sheet information related to leases is as follows: March 31, 2019 Operating leases Other assets (net of lease impairment of $1,325) $ 16,277 Other current liabilities $ 6,810 Other long-term liabilities 11,133 Total operating lease liabilities $ 17,943 Finance leases Property, plant and equipment, gross $ 1,131 Accumulated depreciation (302 ) Property, plant and equipment, net $ 829 Current portion of long-term debt $ 299 Long-term debt 244 Total finance lease liabilities $ 543 Weighted average remaining lease term (in years) Operating leases 3.80 years Finance leases 3.83 years Weighted average discount rate Operating leases 4.41 % Finance leases 4.90 % Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,123 Financing cash flows from finance leases 93 Right-of-use assets obtained in exchange for lease obligations: Operating leases 444 Finance leases — Maturities of lease liabilities as of March 31, 2019 are as follows: Finance Lease Operating Lease Remaining, 2019 $ 260 $ 6,026 2020 219 4,921 2021 21 3,063 2022 76 2,419 2023 — 1,549 2024 — 718 Thereafter — 770 Total lease payments 576 19,466 Less imputed interest (33 ) (1,523 ) Total lease liabilities $ 543 $ 17,943 As of March 31, 2019, we have no additional operating or finance leases that have not yet commenced. Maturities of lease liabilities under ASC 840 are consistent with the above disclosure.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in the net carrying amount of goodwill for the three months ended March 31, 2019 are as follows: Balance as of December 31, 2018 $ 400,440 Goodwill resulting from business acquisition 214,793 Foreign currency translation (81 ) Balance as of March 31, 2019 $ 615,152 Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. During the three months ended March 31, 2019 , the Company acquired Buffalo Filter as further described in Note 3 . Goodwill resulting from the acquisition amounted to $214.8 million and acquired intangible assets including customer and distributor relationships, developed technology and trademarks and tradenames amounted to $141.0 million . Other intangible assets consist of the following: March 31, 2019 December 31, 2018 Weighted Average Amortization Period (Years) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized intangible assets: Customer and distributor relationships 24 $ 339,529 $ (101,057 ) $ 214,577 $ (97,131 ) Sales representation, marketing and promotional rights 25 149,376 (43,500 ) 149,376 (42,000 ) Patents and other intangible assets 15 68,704 (44,783 ) 61,473 (44,242 ) Developed technology 15 100,965 (8,753 ) 91,965 (7,369 ) Unamortized intangible assets: Trademarks and tradenames 86,544 — 86,544 — 22 $ 745,118 $ (198,093 ) $ 603,935 $ (190,742 ) Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”). Amortization expense related to intangible assets which are subject to amortization totaled $7.4 million and $5.5 million in the three months ended March 31, 2019 and 2018 , respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income. Included in developed technology is $5.5 million of earn-out consideration that is considered probable as of March 31, 2019 associated with a prior asset acquisition. This is recorded in other current liabilities at March 31, 2019 . The estimated intangible asset amortization expense remaining for the year ending December 31, 2019 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2019 $ 20,764 $ 4,500 $ 25,264 2020 27,890 6,000 33,890 2021 27,099 6,000 33,099 2022 25,849 6,000 31,849 2023 25,061 6,000 31,061 2024 24,358 6,000 30,358

Guarantees

Guarantees	3 Months Ended
	Mar. 31, 2019
Guarantees [Abstract]
Guarantees	Guarantees We provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally 1 year and our extended warranties typically vary from one to three years. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant. Changes in the carrying amount of service and product standard warranties for the three months ended March 31 , are as follows: 2019 2018 Balance as of January 1, $ 1,585 $ 1,750 Provision for warranties 486 323 Claims made (343 ) (290 ) Balance as of March 31, $ 1,728 $ 1,783 Costs associated with extended warranty repairs are recorded as incurred and amounted to $1.4 million and $1.3 million for the three months ended March 31, 2019 and 2018

Pension Plan

Pension Plan	3 Months Ended
	Mar. 31, 2019
Retirement Benefits [Abstract]
Pension Plan	Pension Plan Net periodic pension cost consists of the following: Three Months Ended March 31, 2019 2018 Service cost $ 253 $ 169 Interest cost on projected benefit obligation 782 701 Expected return on plan assets (1,181 ) (1,354 ) Net amortization and deferral 720 672 Net periodic pension cost $ 574 $ 188 We do not expect to make any pension contributions during 2019 . Non-service cost of $0.3 million is included in other expense in the consolidated condensed statement of comprehensive income for the three months ended March 31, 2019

Acquisition, Restructuring and

Acquisition, Restructuring and Other Expense	3 Months Ended
	Mar. 31, 2019
Acquisition, Restructuring and Other Expense [Abstract]
Acquisition, Restructuring and Other Expense	Acquisition, Restructuring and Other Expense Acquisition, restructuring and other expense consists of the following: Three Months Ended March 31, 2019 2018 Business acquisition costs included in cost of sales $ 660 $ — Business acquisition costs included in selling and administrative expense $ 7,245 $ — Debt refinancing costs included in other expense $ 3,904 $ — During the three months ended March 31, 2019 , we incurred $0.7 million in costs for inventory adjustments associated with the acquisition of Buffalo Filter as further described in Note 3. These costs were charged to cost of sales. During the three months ended March 31, 2019 , we incurred $7.2 million in costs associated with the February 11, 2019 acquisition of Buffalo Filter as further described in Note 3 that were included in selling and administrative expense. These costs include investment banking fees, consulting fees, legal fees and integration related costs. During the three months ended March 31, 2019 , we incurred a $3.6 million charge related to commitment fees paid to certain of our lenders, which provided a financing commitment for the Buffalo Filter acquisition and recorded a loss on the early extinguishment of debt of $0.3 million in conjunction with the sixth amended and restated senior credit agreement as further described in Note 17.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Business Segments	Business Segments We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures including 2DHD and 3DHD vision technologies and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows: Three Months Ended March 31, 2019 2018 Orthopedic surgery $ 113,437 $ 108,862 General surgery 104,941 93,202 Consolidated net sales $ 218,378 $ 202,064

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings From time to time, we are subject to claims alleging product liability, patent infringement or other claims incurred in the ordinary course of business. These may involve our United States or foreign operations, or sales by foreign distributors. Likewise, from time to time, the Company may receive an information request or subpoena from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests or subpoenas may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, we receive reports of alleged misconduct from employees and third parties, which we investigate as appropriate. Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations on manufacturers with respect to interactions with health care providers who may be considered government officials based on their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation. Manufacturers of medical products may face exposure to significant product liability claims. To date, we have not experienced any product liability claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $30 million per incident and $30 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost. We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows. Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows. In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that, if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently, the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice ("the Notice") seeking $12.7 million

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Mar. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), along with amendments issued in 2017 and 2018. This ASU requires lessees to record leases on their balance sheets but recognize the expense on their income statements in a manner similar to current practice. ASU 2016-02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-of-use ("ROU") asset for the right to use the underlying asset for the lease term. The Company adopted the new standard on January 1, 2019, and applied the modified retrospective approach along with the package of transition practical expedients. The Company has lease agreements with lease and non-lease components, which we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The related short-term lease expense is not material. On January 1, 2019, we recorded initial right-of-use assets and lease liabilities, that were previously unrecorded under prior GAAP, of $17.9 million . Operating lease ROU assets are included in other assets and lease liabilities are included in other current liabilities and other long-term liabilities. Our accounting for finance leases, which were capital leases under prior GAAP, remained substantially unchanged. Finance leases are included in property and equipment, current portion of long-term debt and long-term debt in our consolidated balance sheets. This update did not have a material impact on our net income, earnings per share or cash flows. Refer to Note 9 for further detail on leases. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. This ASU makes more financial and non-financial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting and increase transparency as to the scope and results of hedging programs. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted. We adopted this update on January 1, 2019 and it did not have a material impact on our consolidated financial statements. In August 2018, the SEC adopted a final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, that amends certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. The amendments also expanded the disclosure requirements on the analysis of shareholders' equity for interim financial statements, in which registrants must now analyze changes in shareholders’ equity, in the form of reconciliation, for the current and comparative year-to-date periods, with subtotals for each interim period. This final rule was effective on November 5, 2018. The Company adopted all relevant disclosure requirements during the fourth quarter of 2018, with the exception of the shareholders’ equity interim disclosures, which was allowed to be adopted as of January 1, 2019. Recently Issued Accounting Standards, Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires instruments measured at amortized cost, including accounts receivable, to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information, and reasonable and supportable forecasts, including estimates of prepayments. The update is effective for fiscal years beginning after December 31, 2019 and early adoption is permissible during any interim period after December 31, 2018. The Company is currently assessing the impact of this guidance on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This update is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently assessing the impact of this guidance on our consolidated financial statements.

Long-Term Debt (Notes)

Long-Term Debt (Notes)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Long-Term Debt Long-term debt consists of the following: March 31, 2019 December 31, 2018 Revolving line of credit $ 269,000 $ 312,000 Term loan, net of deferred debt issuance costs of $1,826 and $311 in 2019 and 2018, respectively 263,174 144,064 2.625% convertible notes, net of deferred debt issuance costs of $10,508 and unamortized discount of $50,105 in 2019 284,387 — Financing leases 543 — Mortgage notes 836 836 Total debt 817,940 456,900 Less: Current portion 14,385 18,336 Total long-term debt $ 803,555 $ 438,564 On February 7, 2019 we entered into a sixth amended and restated senior credit agreement consisting of: (a) a $265.0 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on the earlier of (i) February 7, 2024 or (ii) 91 days prior to the earliest scheduled maturity date of the 2.625% convertible notes due in 2024 described below, (if, as of such date, more than $150.0 million in aggregate principal amount of such convertible notes (or any refinancing thereof) remains outstanding). The term loan facility is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement and in part to finance the acquisition of Buffalo Filter. Initial interest rates are at LIBOR plus an interest rate margin of 1.875% ( 4.375% at March 31, 2019 ). For those borrowings where we elect to use the alternate base rate, the initial base rate will be the greatest of (i) the Prime Rate, (ii) the Federal Funds Rate plus 0.50% or (iii) the one-month Eurocurrency Rate plus 1.00% , plus, in each case, an interest rate margin. There were $265.0 million in borrowings outstanding on the term loan facility as of March 31, 2019 . There were $269.0 million in borrowings outstanding under the revolving credit facility as of March 31, 2019 . Our available borrowings on the revolving credit facility at March 31, 2019 were $313.0 million with approximately $3.0 million of the facility set aside for outstanding letters of credit. The sixth amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The sixth amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of March 31, 2019 . We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales. On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February 1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert their Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of their Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds from the offering of the notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below. Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.14% , which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes, being attributable to equity. For the three months ended March 31, 2019 , we have recorded interest expense related to the amortization of debt discount on the Notes of $1.5 million at the effective interest rate of 6.14% . The debt discount on the Notes is being amortized through February 2024. For the three months ended March 31, 2019 , we have recorded interest expense on the Notes of $1.6 million , at the contractual coupon rate of 2.625% . In connection with the offering of the Notes, we entered into convertible note hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible note hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes. Concurrently with entering into the convertible note hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock. The convertible note hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price ( $114.92 ) of the convertible note hedge transactions, which initially corresponds to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants, unless we elect to settle the warrants in cash. We have a mortgage note outstanding in connection with the Largo, Florida property and facilities bearing interest at 8.25% per annum with semiannual payments of principal and interest through June 2019. The principal balance outstanding on the mortgage note aggregated $0.8 million at March 31, 2019 . The mortgage note is collateralized by the Largo, Florida property and facilities. The scheduled maturities of long-term debt outstanding at March 31, 2019 are as follows: Remaining, 2019 $ 10,773 2020 13,250 2021 18,219 2022 24,844 2023 467,750 2024 345,000

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), along with amendments issued in 2017 and 2018. This ASU requires lessees to record leases on their balance sheets but recognize the expense on their income statements in a manner similar to current practice. ASU 2016-02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-of-use ("ROU") asset for the right to use the underlying asset for the lease term. The Company adopted the new standard on January 1, 2019, and applied the modified retrospective approach along with the package of transition practical expedients. The Company has lease agreements with lease and non-lease components, which we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The related short-term lease expense is not material. On January 1, 2019, we recorded initial right-of-use assets and lease liabilities, that were previously unrecorded under prior GAAP, of $17.9 million . Operating lease ROU assets are included in other assets and lease liabilities are included in other current liabilities and other long-term liabilities. Our accounting for finance leases, which were capital leases under prior GAAP, remained substantially unchanged. Finance leases are included in property and equipment, current portion of long-term debt and long-term debt in our consolidated balance sheets. This update did not have a material impact on our net income, earnings per share or cash flows. Refer to Note 9 for further detail on leases. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. This ASU makes more financial and non-financial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting and increase transparency as to the scope and results of hedging programs. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted. We adopted this update on January 1, 2019 and it did not have a material impact on our consolidated financial statements. In August 2018, the SEC adopted a final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, that amends certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. The amendments also expanded the disclosure requirements on the analysis of shareholders' equity for interim financial statements, in which registrants must now analyze changes in shareholders’ equity, in the form of reconciliation, for the current and comparative year-to-date periods, with subtotals for each interim period. This final rule was effective on November 5, 2018. The Company adopted all relevant disclosure requirements during the fourth quarter of 2018, with the exception of the shareholders’ equity interim disclosures, which was allowed to be adopted as of January 1, 2019. Recently Issued Accounting Standards, Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires instruments measured at amortized cost, including accounts receivable, to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information, and reasonable and supportable forecasts, including estimates of prepayments. The update is effective for fiscal years beginning after December 31, 2019 and early adoption is permissible during any interim period after December 31, 2018. The Company is currently assessing the impact of this guidance on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This update is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently assessing the impact of this guidance on our consolidated financial statements.

Business Acquisition (Tables)

Business Acquisition (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the Buffalo Filter Acquisition. The assessment of fair value is based on preliminary valuations and estimates that were available to management at the time the consolidated condensed financial statements were prepared. Accordingly, the allocation of purchase price is preliminary and therefore subject to adjustment during the measurement adjustment period. Cash $ 119 Other current assets 9,315 Current assets 9,434 Property, plant & equipment 4,036 Deferred income taxes 80 Goodwill 214,793 Customer relationships 125,000 Developed technology 9,000 Trademarks & tradenames 7,000 Other non-current assets 166 Total assets acquired $ 369,509 Current liabilities assumed 4,462 Total liabilities assumed 4,462 Net assets acquired $ 365,047
Business Acquisition, Pro Forma Information	The unaudited pro forma information for the quarters ended March 31, 2019 and 2018 , assuming Buffalo Filter Acquisition occurred as of January 1, 2018 are presented below. This information has been prepared for comparative purposes only and does not purport to be indicative of the results of operations which actually would have resulted had the Buffalo Filter acquisition occurred on the dates indicated, or which may result in the future. Three Months Ended March 31, 2019 2018 Net sales $ 223,397 $ 211,273 Net income (loss) 8,745 (3,210 )

Revenues (Tables)

Revenues (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended March 31, 2019 March 31, 2018 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 45,256 $ 71,770 $ 117,026 $ 43,152 $ 63,099 $ 106,251 Americas (excluding the United States) 15,042 7,462 22,504 16,771 7,679 24,450 Europe, Middle East & Africa 30,402 15,930 46,332 28,302 12,984 41,286 Asia Pacific 22,737 9,779 32,516 20,637 9,440 30,077 Total sales from contracts with customers $ 113,437 $ 104,941 $ 218,378 $ 108,862 $ 93,202 $ 202,064 Timing of Revenue Recognition Goods transferred at a point in time $ 104,739 $ 104,425 $ 209,164 $ 100,791 $ 92,881 $ 193,672 Services transferred over time 8,698 516 9,214 8,071 321 8,392 Total sales from contracts with customers $ 113,437 $ 104,941 $ 218,378 $ 108,862 $ 93,202 $ 202,064
Contract with Customer, Asset and Liability	Contract liability balances related to the sale of extended warranties to customers are as follows: March 31, 2019 December 31, 2018 Contract liability $ 12,027 $ 11,043

Comprehensive Income (Tables)

Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of Comprehensive Income	Comprehensive income consists of the following: Three Months Ended March 31, 2019 2018 Net income $ 1,021 $ 10,657 Other comprehensive income (loss): Pension liability, net of income tax (income tax expense of $173 and $162 for the three months ended March 31, 2019 and 2018, respectively) 547 510 Cash flow hedging gain, net of income tax (income tax expense of $34 and $505 for the three months ended March 31, 2019 and 2018, respectively) 106 1,586 Foreign currency translation adjustment (578 ) 649 Comprehensive income $ 1,096 $ 13,402
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consists of the following: Cash Flow Hedging Gain (Loss) Pension Liability Cumulative Translation Adjustments Accumulated Other Comprehensive Income (Loss) Balance, December 31, 2018 $ 4,085 $ (31,718 ) $ (28,104 ) $ (55,737 ) Other comprehensive income (loss) before reclassifications, net of tax 1,318 (578 ) 740 Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,598 ) 720 — (878 ) Income tax 386 (173 ) — 213 Net current-period other comprehensive income (loss) 106 547 (578 ) 75 Balance, March 31, 2019 $ 4,191 $ (31,171 ) $ (28,682 ) $ (55,662 ) Cash Flow Hedging Gain (Loss) Pension Liability Cumulative Translation Adjustments Accumulated Other Comprehensive Income (Loss) Balance, December 31, 2017 $ (3,530 ) $ (25,813 ) $ (19,735 ) $ (49,078 ) Other comprehensive income (loss) before reclassifications, net of tax 629 — 649 1,278 Amounts reclassified from accumulated other comprehensive income (loss) before tax a 1,262 672 — 1,934 Income tax (305 ) (162 ) — (467 ) Net current-period other comprehensive income (loss) 1,586 510 649 2,745 Balance, March 31, 2018 $ (1,944 ) $ (25,303 ) $ (19,086 ) $ (46,333 ) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 6 and Note 12

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation March 31, 2019 December 31, 2018 Forward exchange contracts Cash flow hedge $ 155,730 $ 155,313 Forward exchange contracts Non-designated 42,977 39,631
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) and net earnings on our consolidated condensed statement of comprehensive income and our consolidated condensed balance sheet: Amount of Gain (Loss) Recognized in AOCI Statement of Consolidated Condensed of Comprehensive Income Amount of Gain (Loss) Reclassified from AOCI Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, Total Amount of Line Item Presented Derivative Instrument 2019 2018 Location of amount reclassified 2019 2018 2019 2018 Foreign exchange contracts $ 1,738 $ 829 Net Sales $ 218,378 $ 202,064 $ 1,497 $ (1,413 ) Cost of Sales 96,940 92,507 101 151 Pre-tax gain (loss) $ 1,738 $ 829 $ 1,598 $ (1,262 ) Tax expense (benefit) 420 200 386 (305 ) Net gain (loss) $ 1,318 $ 629 $ 1,212 $ (957 )
Derivatives Not Designated as Hedging Instruments	Net gains and losses from derivative instruments not accounted for as hedges offset by gains and losses on our intercompany receivables on our condensed consolidated statements of earnings were: Three Months Ended March 31, Derivative Instrument Location on Consolidated Condensed Statement of Comprehensive Income 2019 2018 Net gain (loss) on currency hedge contracts Selling and administrative expense $ (181 ) $ (69 ) Net gain (loss) on currency transaction exposures Selling and administrative expense $ (229 ) $ (127 )
Schedule of Fair Value for Forward Foreign Exchange Contracts	The following tables summarize the fair value for forward foreign exchange contracts outstanding at March 31, 2019 and December 31, 2018 : March 31, 2019 Location on Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Fair Value Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 5,291 $ (65 ) $ 5,226 Foreign exchange contracts Other long-term assets 428 (128 ) 300 $ 5,719 $ (193 ) $ 5,526 Derivatives not designated as hedging instruments: Foreign exchange contracts Prepaids and other current assets 14 (102 ) (88 ) Total derivatives $ 5,733 $ (295 ) $ 5,438 December 31, 2018 Location on Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Fair Value Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 5,817 $ (431 ) $ 5,386 Derivatives not designated as hedging instruments: Foreign exchange contracts Prepaids and other current assets 19 (217 ) (198 ) Total derivatives $ 5,836 $ (648 ) $ 5,188

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consist of the following: March 31, December 31, Raw materials $ 49,366 $ 45,898 Work-in-process 18,476 15,000 Finished goods 103,245 93,701 Total $ 171,087 $ 154,599

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted earnings per share	The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2019 and 2018 : Three Months Ended March 31, 2019 2018 Net income $ 1,021 $ 10,657 Basic – weighted average shares outstanding 28,173 28,008 Effect of dilutive potential securities 861 565 Diluted – weighted average shares outstanding 29,034 28,573 Net income (per share) Basic $ 0.04 $ 0.38 Diluted 0.04 0.37

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Lease Cost	Lease costs consists of the following: Three Months Ended, March 31, 2019 Operating lease cost $ 1,996 Finance lease cost: Depreciation 53 Interest on lease liabilities 7 Total finance lease cost 60 Total lease cost $ 2,056
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: March 31, 2019 Operating leases Other assets (net of lease impairment of $1,325) $ 16,277 Other current liabilities $ 6,810 Other long-term liabilities 11,133 Total operating lease liabilities $ 17,943 Finance leases Property, plant and equipment, gross $ 1,131 Accumulated depreciation (302 ) Property, plant and equipment, net $ 829 Current portion of long-term debt $ 299 Long-term debt 244 Total finance lease liabilities $ 543 Weighted average remaining lease term (in years) Operating leases 3.80 years Finance leases 3.83 years Weighted average discount rate Operating leases 4.41 % Finance leases 4.90 %
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 2,123 Financing cash flows from finance leases 93 Right-of-use assets obtained in exchange for lease obligations: Operating leases 444 Finance leases —
Operating Lease, Liability, Maturity	Maturities of lease liabilities as of March 31, 2019 are as follows: Finance Lease Operating Lease Remaining, 2019 $ 260 $ 6,026 2020 219 4,921 2021 21 3,063 2022 76 2,419 2023 — 1,549 2024 — 718 Thereafter — 770 Total lease payments 576 19,466 Less imputed interest (33 ) (1,523 ) Total lease liabilities $ 543 $ 17,943
Finance Lease, Liability, Maturity	Maturities of lease liabilities as of March 31, 2019 are as follows: Finance Lease Operating Lease Remaining, 2019 $ 260 $ 6,026 2020 219 4,921 2021 21 3,063 2022 76 2,419 2023 — 1,549 2024 — 718 Thereafter — 770 Total lease payments 576 19,466 Less imputed interest (33 ) (1,523 ) Total lease liabilities $ 543 $ 17,943

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the net carrying amount of goodwill for the three months ended March 31, 2019 are as follows: Balance as of December 31, 2018 $ 400,440 Goodwill resulting from business acquisition 214,793 Foreign currency translation (81 ) Balance as of March 31, 2019 $ 615,152
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets	Other intangible assets consist of the following: March 31, 2019 December 31, 2018 Weighted Average Amortization Period (Years) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized intangible assets: Customer and distributor relationships 24 $ 339,529 $ (101,057 ) $ 214,577 $ (97,131 ) Sales representation, marketing and promotional rights 25 149,376 (43,500 ) 149,376 (42,000 ) Patents and other intangible assets 15 68,704 (44,783 ) 61,473 (44,242 ) Developed technology 15 100,965 (8,753 ) 91,965 (7,369 ) Unamortized intangible assets: Trademarks and tradenames 86,544 — 86,544 — 22 $ 745,118 $ (198,093 ) $ 603,935 $ (190,742 )
Schedule of Estimated Amortization Expense	The estimated intangible asset amortization expense remaining for the year ending December 31, 2019 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2019 $ 20,764 $ 4,500 $ 25,264 2020 27,890 6,000 33,890 2021 27,099 6,000 33,099 2022 25,849 6,000 31,849 2023 25,061 6,000 31,061 2024 24,358 6,000 30,358

Guarantees (Tables)

Guarantees (Tables)	3 Months Ended
	Mar. 31, 2019
Guarantees [Abstract]
Changes in the carrying amount of service and product warranties	Changes in the carrying amount of service and product standard warranties for the three months ended March 31 , are as follows: 2019 2018 Balance as of January 1, $ 1,585 $ 1,750 Provision for warranties 486 323 Claims made (343 ) (290 ) Balance as of March 31, $ 1,728 $ 1,783

Pension Plan (Tables)

Pension Plan (Tables)	3 Months Ended
	Mar. 31, 2019
Retirement Benefits [Abstract]
Schedule of net benefit cost	Net periodic pension cost consists of the following: Three Months Ended March 31, 2019 2018 Service cost $ 253 $ 169 Interest cost on projected benefit obligation 782 701 Expected return on plan assets (1,181 ) (1,354 ) Net amortization and deferral 720 672 Net periodic pension cost $ 574 $ 188

Acquisition, Restructuring an_2

Acquisition, Restructuring and Other Expense (Tables)	3 Months Ended
	Mar. 31, 2019
Acquisition, Restructuring and Other Expense [Abstract]
Schedule of Acquisition, Restructuring and Other Expense	Acquisition, restructuring and other expense consists of the following: Three Months Ended March 31, 2019 2018 Business acquisition costs included in cost of sales $ 660 $ — Business acquisition costs included in selling and administrative expense $ 7,245 $ — Debt refinancing costs included in other expense $ 3,904 $ —

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of net sales information by product line	These product lines' net sales are as follows: Three Months Ended March 31, 2019 2018 Orthopedic surgery $ 113,437 $ 108,862 General surgery 104,941 93,202 Consolidated net sales $ 218,378 $ 202,064

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Long-term debt consists of the following: March 31, 2019 December 31, 2018 Revolving line of credit $ 269,000 $ 312,000 Term loan, net of deferred debt issuance costs of $1,826 and $311 in 2019 and 2018, respectively 263,174 144,064 2.625% convertible notes, net of deferred debt issuance costs of $10,508 and unamortized discount of $50,105 in 2019 284,387 — Financing leases 543 — Mortgage notes 836 836 Total debt 817,940 456,900 Less: Current portion 14,385 18,336 Total long-term debt $ 803,555 $ 438,564
Schedule of Maturities of Long-term Debt [Table Text Block]	The scheduled maturities of long-term debt outstanding at March 31, 2019 are as follows: Remaining, 2019 $ 10,773 2020 13,250 2021 18,219 2022 24,844 2023 467,750 2024 345,000

Business Acquisition (Details)

Business Acquisition (Details) - USD ($) $ in Thousands	Feb. 11, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Payments to acquire businesses, gross	$ 365,000
Cash	119
Other current assets	9,315
Current assets	9,434
Property, plant & equipment	4,036
Deferred income taxes	80
Goodwill		$ 615,152		$ 400,440
Other non-current assets	166
Total assets acquired	369,509
Current liabilities assumed	4,462
Total liabilities assumed	4,462
Net assets acquired	365,047
Goodwill, expected tax deductible amount	214,800
Net sales		223,397	$ 211,273
Net income (loss)		8,745	(3,210)
Net sales		218,378	202,064
Cost of Sales
Business Acquisition [Line Items]
Business acquisition costs		660	0
Selling and Administrative Expenses
Business Acquisition [Line Items]
Business acquisition costs		7,245	0
Buffalo Filter LLC
Business Acquisition [Line Items]
Goodwill	$ 214,793
Weighted average amortization period (in years)	16 years
Net sales		$ 6,100
Customer relationships
Business Acquisition [Line Items]
Intangible assets	$ 125,000
Customer relationships | Buffalo Filter LLC
Business Acquisition [Line Items]
Weighted average amortization period (in years)	16 years
Developed technology
Business Acquisition [Line Items]
Intangible assets	$ 9,000
Developed technology | Buffalo Filter LLC
Business Acquisition [Line Items]
Weighted average amortization period (in years)	10 years
Trademarks & tradenames
Business Acquisition [Line Items]
Intangible assets	$ 7,000
Trademarks & tradenames | Buffalo Filter LLC
Business Acquisition [Line Items]
Weighted average amortization period (in years)	20 years
Pro Forma [Member] | Cost of Sales
Business Acquisition [Line Items]
Business acquisition costs			700
Pro Forma [Member] | Acquisition-related Costs | Selling and Administrative Expenses
Business Acquisition [Line Items]
Business acquisition costs			$ 7,200

Revenues (Disaggregated Revenue

Revenues (Disaggregated Revenues) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Net Sales	$ 218,378	$ 202,064
Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	209,164	193,672
Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	9,214	8,392
Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	113,437	108,862
Orthopedic Surgery | Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	104,739	100,791
Orthopedic Surgery | Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	8,698	8,071
General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	104,941	93,202
General Surgery | Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	104,425	92,881
General Surgery | Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	516	321
United States
Disaggregation of Revenue [Line Items]
Net Sales	117,026	106,251
United States | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	45,256	43,152
United States | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	71,770	63,099
Americas (excluding the United States)
Disaggregation of Revenue [Line Items]
Net Sales	22,504	24,450
Americas (excluding the United States) | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	15,042	16,771
Americas (excluding the United States) | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	7,462	7,679
Europe, Middle East & Africa
Disaggregation of Revenue [Line Items]
Net Sales	46,332	41,286
Europe, Middle East & Africa | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	30,402	28,302
Europe, Middle East & Africa | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	15,930	12,984
Asia Pacific
Disaggregation of Revenue [Line Items]
Net Sales	32,516	30,077
Asia Pacific | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	22,737	20,637
Asia Pacific | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	$ 9,779	$ 9,440

Revenues (Customer Liability) (

Revenues (Customer Liability) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Contract liability	$ 12,027		$ 11,043
Revenue recognized	$ 2,300	$ 1,800

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Equity [Abstract]
Net income	$ 1,021	$ 10,657
Pension liability, net of income tax	547	510
Cash flow hedging gain (loss), net of income tax	106	1,586
Foreign currency translation adjustments	(578)	649
Comprehensive income	1,096	13,402
Pension liability, tax	173	162
Cash flow hedging gain (loss), tax	$ 34	$ 505

Comprehensive Income (Accumulat

Comprehensive Income (Accumulated Other Comprehensive income (loss)) (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss)		$ (55,737)
Accumulated other comprehensive income (loss)		(55,662)
Accumulated Other Comprehensive Loss
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss)		(55,737)	$ (49,078)
Other comprehensive income (loss) before reclassifications		740	1,278
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	(878)	1,934
Reclassification from AOCI, Current Period, Tax		213	(467)
Net current-period other comprehensive income (loss)		75	2,745
Accumulated other comprehensive income (loss)		(55,662)	(46,333)
Cash Flow Hedging Gain (Loss)
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss)		4,085	(3,530)
Other comprehensive income (loss) before reclassifications		1,318	629
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	(1,598)	1,262
Reclassification from AOCI, Current Period, Tax		386	(305)
Net current-period other comprehensive income (loss)		106	1,586
Accumulated other comprehensive income (loss)		4,191	(1,944)
Pension Liability
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss)		(31,718)	(25,813)
Other comprehensive income (loss) before reclassifications			0
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	720	672
Reclassification from AOCI, Current Period, Tax		(173)	(162)
Net current-period other comprehensive income (loss)		547	510
Accumulated other comprehensive income (loss)		(31,171)	(25,303)
Cumulative Translation Adjustments
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated other comprehensive income (loss)		(28,104)	(19,735)
Other comprehensive income (loss) before reclassifications		(578)	649
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	0	0
Reclassification from AOCI, Current Period, Tax		0	0
Net current-period other comprehensive income (loss)		(578)	649
Accumulated other comprehensive income (loss)		$ (28,682)	$ (19,086)
[1]	The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 6 and Note 12

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Derivative [Line Items]
Other Comprehensive Income (Loss), before Reclassifications, before Tax	$ 1,738	$ 829
Net sales	218,378	202,064
Cost of sales	96,940	92,507
Other Comprehensive Income (Loss), Tax	420	200
Other comprehensive income (loss) before reclassifications	1,318	629
Foreign Currency Transaction Gain (Loss), before Tax	(229)	(127)
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	5,733		$ 5,836
Liabilities Fair Value	(295)		(648)
Net Fair Value	5,438		5,188
Foreign Currency Forward Contracts
Derivative [Line Items]
Other Comprehensive Income (Loss), before Reclassifications, before Tax	1,738	829
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(181)	(69)
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	5,719
Liabilities Fair Value	(193)
Net Fair Value	5,526
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Prepaids and other current assets
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	5,291		5,817
Liabilities Fair Value	(65)		(431)
Net Fair Value	5,226		5,386
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other long-term assets
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	428
Liabilities Fair Value	(128)
Net Fair Value	300
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts
Derivative [Line Items]
Notional amount of cash flow hedges	42,977		39,631
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts | Prepaids and other current assets
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	14		19
Liabilities Fair Value	(102)		(217)
Net Fair Value	(88)		(198)
Cash flow hedge | Foreign Currency Forward Contracts
Derivative [Line Items]
Notional amount of cash flow hedges	155,730		$ 155,313
Cash flow hedges realized gains (losses)	1,598	(1,262)
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	4,000
Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net	1,212	(957)
Cash Flow Hedging Gain (Loss)
Derivative [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	386	(305)
Revenues | Cash flow hedge | Foreign Currency Forward Contracts
Derivative [Line Items]
Cash flow hedges realized gains (losses)	1,497	(1,413)
Cost of Sales | Cash flow hedge | Foreign Currency Forward Contracts
Derivative [Line Items]
Cash flow hedges realized gains (losses)	$ 101	$ 151

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 49,366	$ 45,898
Work-in-process	18,476	15,000
Finished goods	103,245	93,701
Total inventory	$ 171,087	$ 154,599

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Net income	$ 1,021	$ 10,657
Basic-weighted average shares outstanding (in shares)	28,173	28,008
Effect of dilutive potential securities (in shares)	861	565
Diluted- weighted average shares outstanding (in shares)	29,034	28,573
Basic (in dollars per share)	$ 0.04	$ 0.38
Diluted (in dollars per share)	$ 0.04	$ 0.37
Antidilutive securities excluded from computation of earnings per share (in shares)	300	400
Option indexed to issuer's equity, strike price (in dollars per share)	$ 114.92

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 1,996
Depreciation	53
Interest on lease liabilities	7
Total finance lease cost	60
Total lease cost	$ 2,056
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining Lease Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining Lease Term	12 years
Lessee, Operating Lease, Renewal Term	5 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Other assets (net of lease impairment of $1,325)	$ 16,277	$ 17,900
Operating Lease, Right-Of-Use Asset, Impairment	1,325
Other current liabilities	6,810
Other long-term liabilities	11,133
Total operating lease liabilities	17,943	$ 17,900
Property, plant and equipment, gross	1,131
Accumulated depreciation	(302)
Property, plant and equipment, net	829
Current portion of long-term debt	299
Long-term debt	244
Total finance lease liabilities	$ 543		$ 0
Weighted average remaining lease term (in years)
Operating leases	3 years 9 months 18 days
Finance leases	3 years 9 months 29 days
Weighted average discount rate
Operating leases	4.41%
Finance leases	4.90%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flows Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,123
Financing cash flows from finance leases	93
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	444
Finance leases	$ 0

Leases - Maturities of Operatin

Leases - Maturities of Operating and Financing Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Finance Lease
Remaining, 2019	$ 260
2020	219
2021	21
2022	76
2023	0
2024	0
Thereafter	0
Total lease payments	576
Less imputed interest	(33)
Total lease liabilities	543		$ 0
Operating Lease
Remaining, 2019	6,026
2020	4,921
2021	3,063
2022	2,419
2023	1,549
2024	718
Thereafter	770
Total lease payments	19,466
Less imputed interest	(1,523)
Total lease liabilities	$ 17,943	$ 17,900

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Goodwill) (Details) - USD ($) $ in Thousands	Feb. 11, 2019	Mar. 31, 2019
Goodwill [Roll Forward]
Beginning balance		$ 400,440
Goodwill resulting from business acquisition	$ 214,800	214,793
Foreign currency translation		(81)
Ending balance		$ 615,152

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Thousands	Feb. 11, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Intangible assets, Accumulated amortization		$ (198,093)		$ (190,742)
Intangible assets, Gross carrying amount		745,118		603,935
Amortization expense		7,400	$ 5,500
Future amortization expense [Abstract]
Remaining, 2019		25,264
2020		33,890
2021		33,099
2022		31,849
2023		31,061
2024		30,358
Amortization included in expense
Future amortization expense [Abstract]
Remaining, 2019		20,764
2020		27,890
2021		27,099
2022		25,849
2023		25,061
2024		24,358
Amortization recorded as a reduction of revenue
Future amortization expense [Abstract]
Remaining, 2019		4,500
2020		6,000
2021		6,000
2022		6,000
2023		6,000
2024		6,000
Trademarks & tradenames
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Unamortized intangible assets, Gross carrying amount		86,544		86,544
Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount		339,529		214,577
Intangible assets, Accumulated amortization		(101,057)		(97,131)
Sales representation, marketing and promotional rights
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount		149,376		149,376
Intangible assets, Accumulated amortization		(43,500)		(42,000)
Patents and other intangible assets
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount		68,704		61,473
Intangible assets, Accumulated amortization		(44,783)		(44,242)
Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount		100,965		91,965
Intangible assets, Accumulated amortization		(8,753)		$ (7,369)
Future amortization expense [Abstract]
Asset Acquisition, Contingent Consideration Liability		$ 5,500
Weighted Average
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)		22 years
Weighted Average | Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)		24 years
Weighted Average | Sales representation, marketing and promotional rights
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)		25 years
Weighted Average | Patents and other intangible assets
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)		15 years
Weighted Average | Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)		15 years
Buffalo Filter LLC
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Weighted average amortization period (in years)	16 years
Buffalo Filter LLC | Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Weighted average amortization period (in years)	16 years
Buffalo Filter LLC | Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible assets acquired	$ 141,000
Weighted average amortization period (in years)	10 years

Guarantees (Details)

Guarantees (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Guarantees [Abstract]
Standard warranty period (in years)	1 year
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance as of January 1,	$ 1,585	$ 1,750
Provision for warranties	486	323
Claims made	(343)	(290)
Balance as of March 31,	1,728	1,783
Extended Product Warranty Disclosure [Abstract]
Product extended warranty expense	$ 1,400	$ 1,300

Pension Plan (Details)

Pension Plan (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Retirement Benefits [Abstract]
Service cost	$ 253	$ 169
Interest cost on projected benefit obligation	782	701
Expected return on plan assets	(1,181)	(1,354)
Net amortization and deferral	720	672
Net periodic pension cost	574	$ 188
Defined Benefit Plan, Non-service cost	$ 300

Acquisition, Restructuring an_3

Acquisition, Restructuring and Other Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Acquisition, Restructuring and Other Expense [Line Items]
Debt Related Commitment Fees and Debt Issuance Costs	$ 3,600
Other expense	4,225	$ 0
Loss on early extinguishment of debt	300	0
Cost of Sales
Acquisition, Restructuring and Other Expense [Line Items]
Business acquisition costs	660	0
Selling and Administrative Expenses
Acquisition, Restructuring and Other Expense [Line Items]
Business acquisition costs	7,245	0
Debt [Member]
Acquisition, Restructuring and Other Expense [Line Items]
Other expense	3,904	$ 0
Fair Value Adjustment to Inventory | Cost of Sales
Acquisition, Restructuring and Other Expense [Line Items]
Business acquisition costs	$ 700

Business Segments (Details)

Business Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Net sales	$ 218,378	$ 202,064
Orthopedic Surgery
Segment Reporting Information [Line Items]
Net sales	113,437	108,862
General Surgery
Segment Reporting Information [Line Items]
Net sales	$ 104,941	$ 93,202

Legal Proceedings (Details)

Legal Proceedings (Details) - USD ($) $ in Millions	Jan. 18, 2017	Mar. 31, 2019
Loss Contingencies [Line Items]
Product liability insurance, amount per incident		$ 30
Product liability insurance, aggregate annual amount		$ 30
Pending Litigation | EndoDynamix, Inc.
Loss Contingencies [Line Items]
Damages sought	$ 12.7

New Accounting Pronouncements N

New Accounting Pronouncements New Accounting Pronouncements (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Operating lease, right-of-use asset	$ 16,277	$ 17,900
Total lease liabilities	$ 17,943	$ 17,900

Long-Term Debt - Schedule of De

Long-Term Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total debt	$ 817,940	$ 456,900
Financing leases	543	0
Less: Current portion	14,385	18,336
Total long-term debt	803,555	438,564
Revolving line of credit
Debt Instrument [Line Items]
Total debt	269,000	312,000
Term loan, net of deferred debt issuance costs of $1,826 and $311 in 2019 and 2018, respectively
Debt Instrument [Line Items]
Total debt	263,174	144,064
Unamortized debt issuance cost	1,826	311
2.625% convertible notes, net of deferred debt issuance costs of $10,508 and unamortized discount of $50,105 in 2019
Debt Instrument [Line Items]
Convertible Debt	284,387	0
Unamortized debt issuance cost	10,508	0
Unamortized discount	50,105	0
Mortgage notes
Debt Instrument [Line Items]
Total debt	$ 836	$ 836

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($)	Jan. 29, 2019	Mar. 31, 2019	Mar. 31, 2018	Feb. 07, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term debt		$ 817,940,000			$ 456,900,000
Option indexed to issuer's equity, strike price (in dollars per share)		$ 114.92
Amortization of debt discount		$ 1,510,000	$ 0
Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross		265,000,000
Long-term debt		263,174,000			144,064,000
Loans Payable | Amended and Restated Senior Credit Agreement
Debt Instrument [Line Items]
Face amount				$ 265,000,000
Revolving line of credit
Debt Instrument [Line Items]
Long-term debt		269,000,000			312,000,000
Remaining borrowing capacity		313,000,000
Revolving line of credit | Amended and Restated Senior Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 585,000,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding, amount		3,000,000
Convertible Notes Payable
Debt Instrument [Line Items]
Debt Instrument, Convertible, Gross Amount of Equity Component	$ (51,600,000)
Equity component of convertible debt	39,100,000
Convertible Notes Payable | 2.625% Convertible Notes Due 2024
Debt Instrument [Line Items]
Face amount	$ 345,000,000
Interest rate, stated percentage	2.625%
Interest rate, effective percentage	6.14%
Interest expense, debt		$ 1,600,000
Initial conversion rate	11.2608
Conversion price (in dollars per share)	$ 88.80
Long-term Debt | Amended and Restated Senior Credit Agreement
Debt Instrument [Line Items]
Interest rate, effective percentage		4.375%
Mortgage notes
Debt Instrument [Line Items]
Long-term debt		$ 836,000			$ 836,000
Mortgage notes | Largo, Florida Mortgage
Debt Instrument [Line Items]
Long-term debt		$ 800,000
London Interbank Offered Rate (LIBOR) | Long-term Debt | Amended and Restated Senior Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate		1.875%
Federal Funds Effective Swap Rate | Long-term Debt | Amended and Restated Senior Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Eurodollar | Long-term Debt | Amended and Restated Senior Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate		1.00%
Call Option
Debt Instrument [Line Items]
Hedge and warrant transactions, net cash paid	$ 21,000,000

Long-Term Debt - Maturities of

Long-Term Debt - Maturities of Long Term Debt (Details) $ in Thousands	Mar. 31, 2019USD ($)
Debt Disclosure [Abstract]
Remaining, 2019	$ 10,773
2020	13,250
2021	18,219
2022	24,844
2023	467,750
2024	$ 345,000